These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 33861536)

  • 1. Hypertrophic cardiomyopathy considerations for the managed care pharmacist.
    Taddei-Allen P
    Am J Manag Care; 2021 Apr; 27(6 Suppl):S118-S125. PubMed ID: 33861536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of hypertrophic cardiomyopathy.
    Enriquez AD; Goldman ME
    Ann Glob Health; 2014; 80(1):35-45. PubMed ID: 24751563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators.
    Maron BJ; Casey SA; Olivotto I; Sherrid MV; Semsarian C; Autore C; Ahmed A; Boriani G; Francia P; Winters SL; Giudici M; Koulova A; Garberich R; Rowin EJ; Sears SF; Maron MS; Spirito P
    Circ Arrhythm Electrophysiol; 2018 Apr; 11(4):e005820. PubMed ID: 29625970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine.
    Maron BJ; Ommen SR; Semsarian C; Spirito P; Olivotto I; Maron MS
    J Am Coll Cardiol; 2014 Jul; 64(1):83-99. PubMed ID: 24998133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypertrophic cardiomyopathy: a review of etiology and treatment.
    Jurynec J
    J Cardiovasc Nurs; 2007; 22(1):65-73; quiz 74-5. PubMed ID: 17224700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current perspectives in hypertrophic cardiomyopathy with the focus on patients in the Finnish population: a review.
    Kuusisto J; Sipola P; Jääskeläinen P; Naukkarinen A
    Ann Med; 2016 Nov; 48(7):496-508. PubMed ID: 27460395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of hypertrophic cardiomyopathy in children.
    Seggewiss H; Rigopoulos A
    Paediatr Drugs; 2003; 5(10):663-72. PubMed ID: 14510624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypertrophic cardiomyopathy: a systematic review.
    Maron BJ
    JAMA; 2002 Mar; 287(10):1308-20. PubMed ID: 11886323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hypertrophic cardiomyopathy: current aspects and new developments].
    Desnos M
    Bull Acad Natl Med; 2012; 196(4-5):997-1009; discussion 1009-10. PubMed ID: 23550458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical characteristics of hypertrophic cardiomyopathy in children: An 8-year single center experience.
    Tunca Sahin G; Ozgur S; Kafali HC; Sevinc Sengul F; Haydin S; Guzeltas A; Ergul Y
    Pediatr Int; 2021 Jan; 63(1):37-45. PubMed ID: 32682351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcomes after medical and invasive treatment in patients with hypertrophic cardiomyopathy.
    Vriesendorp PA; Liebregts M; Steggerda RC; Schinkel AF; Willems R; Ten Cate FJ; van Cleemput J; Ten Berg JM; Michels M
    JACC Heart Fail; 2014 Dec; 2(6):630-6. PubMed ID: 25447346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paradigm of Sudden Death Prevention in Hypertrophic Cardiomyopathy.
    Maron BJ; Rowin EJ; Maron MS
    Circ Res; 2019 Aug; 125(4):370-378. PubMed ID: 31518168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current and emerging perspectives on pathophysiology, diagnosis, and management of hypertrophic cardiomyopathy.
    Gartzonikas IK; Naka KK; Anastasakis A
    Hellenic J Cardiol; 2023; 70():65-74. PubMed ID: 36403865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low Risk of Hypertrophic Cardiomyopathy With Contemporary Management Strategies Implemented in Non-Referral Regional Community-Based Practices.
    Shirani J; Aurshiya R; Elshaikh A; Olenchock SA; Rowin EJ; Maron MS; Maron BJ
    Am J Cardiol; 2021 Mar; 142():130-135. PubMed ID: 33279482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence, Clinical Characteristics, and Long-term Outcome of the Dilated Phase of Hypertrophic Cardiomyopathy.
    Aizawa Y; Tanimoto Y; Hirata Y; Fujisawa T; Fukuoka R; Nakajima K; Katsumata Y; Nishiyama T; Kimura T; Yuasa S; Kohno T; Kohsaka S; Murata M; Maekawa Y; Furukawa Y; Takatsuki S; Fukuda K
    Keio J Med; 2019 Dec; 68(4):87-94. PubMed ID: 30606897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Interventional treatment in hypertrophic cardiomyopathy].
    Gietzen FH; Schümmelfeder J; Neuser H; Brunn J; Schumacher B; Kerber S
    Herz; 2005 Mar; 30(2):102-10. PubMed ID: 15875098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypertrophic Cardiomyopathy in Children, Adolescents, and Young Adults Associated With Low Cardiovascular Mortality With Contemporary Management Strategies.
    Maron BJ; Rowin EJ; Casey SA; Lesser JR; Garberich RF; McGriff DM; Maron MS
    Circulation; 2016 Jan; 133(1):62-73. PubMed ID: 26518766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Familial Hypertrophic Cardiomyopathy: Diagnosis and Management.
    Litt MJ; Ali A; Reza N
    Vasc Health Risk Manag; 2023; 19():211-221. PubMed ID: 37050929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy.
    Rowin EJ; Hausvater A; Link MS; Abt P; Gionfriddo W; Wang W; Rastegar H; Estes NAM; Maron MS; Maron BJ
    Circulation; 2017 Dec; 136(25):2420-2436. PubMed ID: 28916640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypertrophic Cardiomyopathy-Related Sudden Cardiac Death in Young People in Ontario.
    Weissler-Snir A; Allan K; Cunningham K; Connelly KA; Lee DS; Spears DA; Rakowski H; Dorian P
    Circulation; 2019 Nov; 140(21):1706-1716. PubMed ID: 31630535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.